Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00408681 · OUTCOME

Agents Added to Treat GVHD More Than 3 Days After Enrollment

Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant · Source last updated 2017-03-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Up to 100 days after enrollment

What was measured

Any systemic medication given in an effort to control graft-versus-host disease

Groups in this outcome

Treated Patients

Patients received oral lithium carbonate once or twice daily. Treatment continued for up to 8 weeks in the absence of disease progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treated Patients20

Reported measurements

Methotrexate
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treated Patients1Not reportedNot reportedNot reportedNot reported
Pentostatin
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treated Patients1Not reportedNot reportedNot reportedNot reported
Rabbit anti-thymocyte globulin
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treated Patients5Not reportedNot reportedNot reportedNot reported
Mycophenolate mofetil
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treated Patients4Not reportedNot reportedNot reportedNot reported
Tacrolimus
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treated Patients2Not reportedNot reportedNot reportedNot reported
Infliximab
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treated Patients4Not reportedNot reportedNot reportedNot reported
Etanercept
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treated Patients1Not reportedNot reportedNot reportedNot reported
Alemtuzumab
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treated Patients1Not reportedNot reportedNot reportedNot reported
Sirolimus
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treated Patients6Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    Methotrexate
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    Pentostatin
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        5
    title
    Rabbit anti-thymocyte globulin
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        4
    title
    Mycophenolate mofetil
  5. categories
    1. measurements
      1. group Id
        OG000
        value
        2
    title
    Tacrolimus
  6. categories
    1. measurements
      1. group Id
        OG000
        value
        4
    title
    Infliximab
  7. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    Etanercept
  8. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    Alemtuzumab
  9. categories
    1. measurements
      1. group Id
        OG000
        value
        6
    title
    Sirolimus
denoms
  1. counts
    1. group Id
      OG000
      value
      20
    units
    Participants
description
Any systemic medication given in an effort to control graft-versus-host disease
groups
  1. description
    Patients received oral lithium carbonate once or twice daily. Treatment continued for up to 8 weeks in the absence of disease progression or unacceptable toxicity.
    id
    OG000
    title
    Treated Patients
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
Up to 100 days after enrollment
title
Agents Added to Treat GVHD More Than 3 Days After Enrollment
type
OTHER_PRE_SPECIFIED
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice